(Q44318804)

1 December 2017

Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells (English)

1 reference

1 December 2017

1 reference

Hamel FG

1

1 reference

1 December 2017

Fawcett J

2

1 reference

1 December 2017

Tsui BT

3

1 reference

1 December 2017

Bennett RG

4

1 reference

1 December 2017

Duckworth WC

5

1 reference

1 December 2017

1 November 2006

1 reference

Diabetes, Obesity and Metabolism

1 December 2017

1 reference

1 December 2017

8

1 reference

1 December 2017

6

1 reference

1 December 2017

661-668

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Insulin resistance in HIV protease inhibitor-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Protease inhibitor-induced lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Anti-retroviral therapy, insulin resistance and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Purification of insulin-specific protease by affinity chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

How an inhibitor of the HIV-I protease modulates proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

HIV protease inhibitor-related lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

The human 26S proteasome is a target of antiretroviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

In VitroInhibition of Insulin-Degrading Enzyme by Long-Chain Fatty Acids and Their Coenzyme A Thioesters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00546.X

10.1111/J.1463-1326.2005.00546.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference